We are in the process of revising our surgical prophylaxis guidelines and are struggling with management of patients receiving current scheduled therapy (e.g. extended infusion pip/tazo, scheduled vanco) especially when administration times fall outside of the recommended window. There are no clear guidelines from our review.
How has your organization addressed this component?
I'd be happy to compile a response summary.
We've also capped the maximum number of intra-operative re-doses at three.
Thanks!
Andrea